The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
Docomo is looking to expand its reach beyond Japan and sees India and Africa as key emerging markets.
CCI has accused realty player DLF of preparing one-sided agreement with home buyers
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
The Civil Aviation Ministry is looking to increase air seat entitlement to Dubai by 20%.
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Formal announcement of venture into new segment on Thursday; group's entry timely, given the demand, say experts
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
.jpg)
The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.
Many of the industrialists profiled in the book are no longer riding the wave of success.
DFS writes to departments that haven't responded to RBI's request for information.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances